Penumbra, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Penumbra, Inc. - overview
Established
2004
Location
Alameda, CA, US
Primary Industry
Healthcare
About
Penumbra, Inc. develops innovative medical devices focused on improving treatment outcomes for patients with acute ischemic stroke and various vascular conditions through advanced technologies and specialized therapies. Founded in 2004 and headquartered in Alameda, US, Penumbra, Inc. specializes in medical device development.
The company has engaged in 7 deals, with its latest funding round being an IPO in September 2015, raising USD 120 mn. The company is led by CEO Adam Elsesser and Raffaele Venafro. Penumbra, Inc. specializes in developing advanced medical devices aimed at transforming the treatment of acute ischemic stroke and other vascular conditions.
Their core offerings include the Penumbra Reperfusion Catheters and Separators, integral to the PENUMBRA SYSTEM, designed for revascularization in stroke patients. Additionally, the Penumbra Aspiration Pump and Sterile Aspiration Tubing are essential for effective thrombus removal. These products primarily serve hospitals and medical facilities in the United States, enhancing acute care treatment. In the most recent year, Penumbra, Inc.
reported a revenue of USD 1,194. 62 mn and an EBITDA of USD 44. 57 mn. Their revenue model is centered on the sale of proprietary medical devices, focusing on B2B transactions with hospitals and healthcare providers, which underpins their business strategy in the healthcare sector.
Penumbra, Inc. plans to leverage the USD 120 mn raised from its IPO in September 2015 to enhance its product offerings and expand into new geographic regions. The company aims to launch upcoming products designed for advanced vascular therapies, targeting markets in Europe and Asia by 2025. This strategic expansion will be supported by the funding from their recent deal, facilitating the development of innovative solutions for stroke treatment.
Primary Industry
Healthcare
Sub Industries
Diagnostic, Medical & Imaging Laboratories, Medical Devices & Equipment, Pharmaceutical Research & Development
Website
www.penumbrainc.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Penumbra, Inc. - timeline of key events
Penumbra, Inc. - financials
| Fiscal Year Ended | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 186,095,000 | 263,317,000 | 333,764,000 | 444,938,000 | 547,405,000 | 560,412,000 | 747,590,000 | 847,133,000 | - | - | - |
| % Revenue Growth (YoY) | - | 41.5% | 26.8% | 33.3% | 23.0% | 2.4% | 33.4% | 13.3% | - | - | - |
| EBITDA (USD) | 6,014,000 | 1,944,000 | 5,537,000 | 5,155,000 | 55,612,000 | (26,051,000) | 8,907,000 | 30,403,000 | - | - | - |
| Operating Income (USD) | 4,179,000 | (1,350,000) | 1,165,000 | (852,000) | 47,508,000 | (38,942,000) | (7,501,000) | 6,082,000 | - | - | - |
| Operating Margin | 2.2% | (0.5%) | 0.3% | (0.2%) | 8.7% | (6.9%) | (1.0%) | 0.7% | - | - | - |
| % EBITDA Margin | 3.2% | 0.7% | 1.7% | 1.2% | 10.2% | (4.6%) | 1.2% | 3.6% | - | - | - |
| NET Income (USD) | 2,365,000 | 14,814,000 | 4,657,000 | 2,910,000 | 47,004,000 | (19,257,000) | 2,623,000 | (2,002,000) | - | - | - |
| % Net Margin | 1.3% | 5.6% | 1.4% | 0.7% | 8.6% | (3.4%) | 0.4% | (0.2%) | - | - | - |
Penumbra, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.